NasdaqGS - Delayed Quote USD

Black Diamond Therapeutics, Inc. (BDTX)

5.01 -0.01 (-0.20%)
At close: 4:00 PM EDT
5.01 0.00 (0.00%)
After hours: 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Mark A. Velleca M.D., Ph.D. CEO, President & Chairman 43.89k -- 1964
Dr. David M. Epstein Ph.D. Co-Founder & Director 885.08k -- 1959
Dr. Fang Ni Pharm.D. CFO, Principal Financial Officer and Chief Business Officer 656.33k -- 1987
Mr. Brent Hatzis-Schoch Esq., J.D. COO & General Counsel 683.29k -- 1965
Dr. Elizabeth Buck Ph.D. Co-Founder & Chief Scientific Officer 340.47k -- 1975
Ms. Erika Jones VP of Finance, Corporate Controller & Principal Accounting Officer -- -- 1985
Ms. Elizabeth L. Montgomery Chief People Officer -- -- 1972
Dr. Sergey Yurasov M.D., Ph.D. Chief Medical Officer -- -- 1969
Ms. Melanie Morrison Chief Development Officer -- -- --

Black Diamond Therapeutics, Inc.

One Main Street
14th Floor
Cambridge, MA 02142
United States
617 252 0848 https://www.blackdiamondtherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
54

Description

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Black Diamond Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Black Diamond Therapeutics, Inc. Earnings Call

Related Tickers

ALXO ALX Oncology Holdings Inc.
15.50
+8.92%
 
NKTX Nkarta, Inc.
7.56
+2.30%
 
CGEM Cullinan Therapeutics, Inc.
16.67
+6.65%
 
PASG Passage Bio, Inc.
1.2300
+7.89%
 
CABA Cabaletta Bio, Inc.
13.32
0.00%
 
BCEL Atreca, Inc.
0.0800
-5.88%
 
STOK Stoke Therapeutics, Inc.
11.25
0.00%
 
RANI Rani Therapeutics Holdings, Inc.
6.69
+0.30%
 
ADCT ADC Therapeutics SA
4.9700
+6.20%
 
RVMD Revolution Medicines, Inc.
36.26
-0.47%